BIOCRYST chief R&D officer files initial Form 3

BIOCRYST PHARMACEUTICALS INC filed an initial Form 3 for Chief R&D Officer Sandeep Menon.

Rhea-AI Filing Summary

BIOCRYST PHARMACEUTICALS INC filed an initial Form 3 for Chief R&D Officer Sandeep Menon. This document establishes his status as a reporting insider at the company. The filing does not list any transactions, so it serves mainly as a baseline disclosure of his insider reporting obligations.

Key Terms

Form 3, Chief R&D Officer, reporting insider

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Chief R&D Officer financial

""officer_title": "Chief R&D Officer""

reporting insider regulatory

"establishes his status as a reporting insider at the company"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the BIOCRYST PHARMACEUTICALS (BCRX) Form 3 for Sandeep Menon mean?

The Form 3 for Sandeep Menon is an initial insider ownership statement. It identifies him as a reporting insider of BIOCRYST PHARMACEUTICALS and establishes baseline disclosure. The filing reports no transactions, focusing solely on his status as Chief R&D Officer subject to SEC reporting rules.

Did Sandeep Menon report any BIOCRYST PHARMACEUTICALS (BCRX) share transactions on this Form 3?

No transactions are reported on this Form 3 for Sandeep Menon. The transaction summary shows zero buys, zero sells, and no derivative exercises. It functions purely as an initial registration of his insider status rather than a record of trading activity in BIOCRYST shares.

What insider role does Sandeep Menon hold at BIOCRYST PHARMACEUTICALS (BCRX)?

Sandeep Menon is listed as an officer of BIOCRYST PHARMACEUTICALS, serving as Chief R&D Officer. This role makes him a Section 16 reporting person, requiring filings such as Form 3, Form 4, and Form 5 to disclose his ownership and relevant changes in company securities.

How many BIOCRYST PHARMACEUTICALS (BCRX) derivative positions are shown in Sandeep Menon’s Form 3?

The Form 3 derivative summary for Sandeep Menon is empty, indicating no reportable derivative positions in this filing. There are no options, warrants, or other derivative securities listed, so the document focuses solely on establishing his insider reporting status at BIOCRYST.

Does the BIOCRYST PHARMACEUTICALS (BCRX) Form 3 for Sandeep Menon show any net buying or selling?

The transaction summary shows a net buy/sell direction of neutral with zero shares. This means no net buying or selling activity is disclosed. The Form 3 is therefore a baseline ownership filing rather than evidence of recent trading decisions by Sandeep Menon.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/07/2026 - 04:22 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Menon Sandeep

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/06/2026

3. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief R&D Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Alane P. Barnes, by power of attorney	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)